Regeneron Pharmaceuticals (NASDAQ:REGN) Lowered to Buy Rating by Wall Street Zen

Key Points

• Wall Street Zen downgraded Regeneron Pharmaceuticals from “strong buy” to “buy,” while broader analyst sentiment remains positive with a “Moderate Buy” consensus and an average price target of $802.18.
• Regeneron reported strong quarterly results, earning $14.29 per share versus the $10.16 estimate and generating $4.29 billion in revenue, up 16.7% year over year.
• Insiders sold 4,146 shares worth approximately $3.43 million over the past 90 days, while institutional investors and hedge funds own 83.31% of the company.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) was downgraded by analysts at Wall Street Zen from a "strong-buy" rating to a "buy" rating in a report issued on Saturday, Wall Street Zen reports.

Other equities research analysts also recently issued research reports about the company. Benchmark raised Regeneron Pharmaceuticals from a "hold" rating to a "buy" rating and set a $185.00 target price for the company in a research report on Tuesday, July 7th. Weiss Ratings reiterated a "hold (c)" rating on shares of Regeneron Pharmaceuticals in a report on Wednesday, June 24th. Piper Sandler reduced their price target on Regeneron Pharmaceuticals from $855.00 to $854.00 and set an "overweight" rating on the stock in a research report on Thursday, July 9th. Royal Bank Of Canada upped their price target on Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the stock a "sector perform" rating in a report on Friday, July 31st. Finally, Citigroup upped their price target on Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the stock a "neutral" rating in a report on Monday, August 3rd. Fourteen investment analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company's stock. According to data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $802.18.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $781.49 on Friday. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. The company has a market cap of $80.46 billion, a PE ratio of 19.32, a P/E/G ratio of 1.56 and a beta of 0.20. The company's fifty day simple moving average is $754.93 and its 200-day simple moving average is $720.58. Regeneron Pharmaceuticals has a 52 week low of $541.00 and a 52 week high of $859.34.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, topping analysts' consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The firm had revenue of $4.29 billion during the quarter, compared to analysts' expectations of $3.82 billion. During the same period in the prior year, the company earned $12.81 EPS. The firm's revenue was up 16.7% on a year-over-year basis. As a group, equities research analysts anticipate that Regeneron Pharmaceuticals will post 44.25 EPS for the current year.

Insiders Place Their Bets

In related news, Director Huda Y. Zoghbi sold 800 shares of the stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the completion of the transaction, the director owned 1,703 shares of the company's stock, valued at approximately $1,362,400. This represents a 31.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Arthur F. Ryan sold 200 shares of the stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total value of $130,030.00. Following the completion of the transaction, the director directly owned 17,303 shares of the company's stock, valued at $11,249,545.45. This represents a 1.14% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 4,146 shares of company stock valued at $3,432,488 over the last ninety days. Insiders own 6.97% of the company's stock.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the business. California State Teachers Retirement System boosted its stake in Regeneron Pharmaceuticals by 63,274.2% during the 2nd quarter. California State Teachers Retirement System now owns 97,723,683 shares of the biopharmaceutical company's stock valued at $60,934,625,000 after acquiring an additional 97,569,482 shares during the last quarter. BlackRock Inc. bought a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth about $5,682,636,000. Norges Bank bought a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth about $1,012,296,000. Price T Rowe Associates Inc. MD raised its stake in shares of Regeneron Pharmaceuticals by 142.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,949,797 shares of the biopharmaceutical company's stock valued at $1,504,991,000 after purchasing an additional 1,144,887 shares in the last quarter. Finally, Nuveen LLC raised its stake in shares of Regeneron Pharmaceuticals by 71.1% in the 4th quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company's stock valued at $1,551,858,000 after purchasing an additional 835,240 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: RBC said Regeneron is increasingly likely to retain key patent protection for Eylea HD, a major commercial product. Preserving exclusivity could help protect revenue and earnings from biosimilar competition. Regeneron Pharmaceuticals More Likely to Retain Eylea HD Patent, RBC Says
• Positive Sentiment: HSBC raised its price target on REGN to $920 from $800 and maintained a Buy rating, implying substantial upside from the referenced share price. The move signals improved confidence in Regeneron’s outlook. HSBC Raises Regeneron Price Target
• Neutral Sentiment: A reported September short-interest figure of zero shares is not actionable because it is inconsistent with normal market data and produces a zero-day short-interest ratio.
• Negative Sentiment: Multiple law firms are promoting a securities class action against Regeneron, with a September 14 deadline for investors to seek lead-plaintiff status. The repeated notices add reputational and potential legal-cost risks, although they largely repeat the same lawsuit information rather than announce a new development. Regeneron Investor Deadline and Class Action Lawsuit
• Negative Sentiment: The lawsuit stems from the failure of a Phase 3 melanoma trial involving the Fianlimab-Libtayo therapy and allegations that Regeneron minimized statistical and protocol risks, including issues affecting progression-free-survival analysis. The trial failure reportedly erased about $11 billion in market value and raises concerns about the company’s pipeline and disclosure practices. Regeneron Clinical-Trial Risk Disclosure Lawsuit

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses technologies involving genetics, antibodies and other biologic treatments to advance therapies in areas such as eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease and rare disorders.

Regeneron's marketed medicines include EYLEA and EYLEA HD for retinal diseases, Libtayo for certain cancers, Praluent for cardiovascular disease, Evkeeza for homozygous familial hypercholesterolemia and Veopoz for a rare immune disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.